Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

NCT02415413 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Smoldering Multiple Myeloma

Interventions

DRUG: carfilzomib
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Melphalan

Sponsor

PETHEMA Foundation

Collaborators

[object Object]
[object Object]